Mukesh Harisinghani
Overview
Explore the profile of Mukesh Harisinghani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
95
Citations
1424
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hampilos P, Luppi A, Ghoshhajra B, Gee M, Harisinghani M, Hedgire S
Int J Cardiovasc Imaging
. 2025 Jan;
PMID: 39870959
The use of conventional contrast agents in computed tomography (CT) and magnetic resonance (MR) imaging is often limited in patients with chronic kidney disease (CKD) due to potential nephrotoxicity. Ferumoxytol,...
2.
Li O, Hamadeh A, Pourvaziri A, Mercaldo S, Clark J, McLay K, et al.
Curr Probl Diagn Radiol
. 2024 Oct;
PMID: 39419703
Purpose: To determine differentiating CT imaging features of primary ovarian cancers from ovarian metastases of gastrointestinal origin. Methods: Retrospective study of 50 patients with new ovarian lesions on CT, half...
3.
Beyer C, Andersson A, Shumbayawonda E, Alkhouri N, Alkouri N, Banerjee A, et al.
J Magn Reson Imaging
. 2024 Sep;
61(4):1947-1955.
PMID: 39319470
Background: Quantitative magnetic resonance imaging metrics iron-corrected T1 (cT1) and liver fat from proton density fat-fraction (PDFF) are both commonly used as noninvasive biomarkers for metabolic dysfunction-associated steatohepatitis (MASH); however,...
4.
Rouhezamin M, Lee S, Harisinghani M, Uppot R
Curr Probl Diagn Radiol
. 2024 Aug;
54(2):251-264.
PMID: 39183071
Objective: The purpose of this article is to review the staging systems for common malignant genitourinary and gynecological tumors, including renal cell carcinoma, urinary bladder carcinoma, as well as cervical,...
5.
Li H, Liu H, von Busch H, Grimm R, Huisman H, Tong A, et al.
Radiol Artif Intell
. 2024 Aug;
6(5):e230521.
PMID: 39166972
Purpose To determine whether the unsupervised domain adaptation (UDA) method with generated images improves the performance of a supervised learning (SL) model for prostate cancer (PCa) detection using multisite biparametric...
6.
Timms L, Zhou T, Qiao J, Gharagouzloo C, Mishra V, Lahoud R, et al.
Int J Biomed Imaging
. 2024 Apr;
2024:9763364.
PMID: 38644981
Background: Ferumoxytol (Ferahame, AMAG Pharmaceuticals, Waltham, MA) is increasingly used off-label as an MR contrast agent due to its relaxivity and safety profiles. However, its potent T2 relaxivity limits achievable...
7.
Promsorn J, Naknan P, Sookprasert A, Wirasorn K, Chindaprasirt J, Titapun A, et al.
Heliyon
. 2024 Apr;
10(7):e28805.
PMID: 38617950
Objective: To study which radiographic features were associated with recurrence and adverse outcome in patients undergoing surgical resection of perihilar cholangiocarcinoma (PCCA), as well as to evaluate the imaging patterns...
8.
Alkhouri N, Harisinghani M
Hepatology
. 2023 Nov;
79(4):E119-E120.
PMID: 37939217
No abstract available.
9.
Chuang H, Wu S, Lin S, Zhao T, Kim M, Harisinghani M, et al.
Diagn Pathol
. 2023 Sep;
18(1):101.
PMID: 37697349
Background: Extraprostatic extension (EPE) of prostate cancer (PCa) on transrectal (TR) needle core biopsy (Bx) is a rare histopathological finding that can help in clinical decision-making. The detection efficiency of...
10.
Salari K, Kowitz J, Twum-Ampofo J, Gusev A, OShea A, Anderson M, et al.
Urol Oncol
. 2023 May;
41(9):387.e9-387.e16.
PMID: 37208229
Objective: Most prostate cancer active surveillance (AS) protocols suggest a confirmatory biopsy within 12 to 18 months of diagnosis to mitigate the risk of unsampled high-grade disease. We investigate whether...